Zions Bancorporation N.A. Has $2.03 Million Stake in Repligen Co. (NASDAQ:RGEN)

Zions Bancorporation N.A. grew its position in Repligen Co. (NASDAQ:RGEN) by 48.9% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 14,079 shares of the biotechnology company’s stock after purchasing an additional 4,626 shares during the period. Zions Bancorporation N.A.’s holdings in Repligen were worth $2,027,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in the company. Quest Partners LLC acquired a new stake in shares of Repligen during the third quarter worth approximately $166,000. Charles Schwab Investment Management Inc. increased its holdings in Repligen by 1.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 363,379 shares of the biotechnology company’s stock valued at $54,078,000 after purchasing an additional 5,478 shares in the last quarter. Raymond James Trust N.A. raised its position in Repligen by 20.9% in the 3rd quarter. Raymond James Trust N.A. now owns 2,750 shares of the biotechnology company’s stock valued at $409,000 after purchasing an additional 475 shares during the last quarter. Cerity Partners LLC raised its holdings in shares of Repligen by 90.0% in the third quarter. Cerity Partners LLC now owns 5,541 shares of the biotechnology company’s stock valued at $825,000 after buying an additional 2,625 shares during the last quarter. Finally, Bank of Montreal Can lifted its position in Repligen by 34.9% during the 3rd quarter. Bank of Montreal Can now owns 49,568 shares of the biotechnology company’s stock worth $7,233,000 after buying an additional 12,816 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on RGEN shares. TD Cowen started coverage on shares of Repligen in a research note on Monday, February 10th. They issued a “buy” rating and a $200.00 target price for the company. JPMorgan Chase & Co. upped their price objective on Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a report on Friday, February 21st. HC Wainwright reissued a “buy” rating and issued a $180.00 target price on shares of Repligen in a research note on Friday, February 21st. Evercore ISI assumed coverage on Repligen in a research report on Tuesday, March 18th. They set an “in-line” rating and a $155.00 target price for the company. Finally, Canaccord Genuity Group assumed coverage on Repligen in a research report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $178.64.

Insider Transactions at Repligen

In other Repligen news, Director Margaret Pax acquired 250 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The stock was acquired at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the transaction, the director now owns 1,043 shares of the company’s stock, valued at $157,169.67. This trade represents a 31.53 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.20% of the stock is currently owned by insiders.

Repligen Stock Down 2.2 %

Repligen stock opened at $141.95 on Wednesday. The firm has a market capitalization of $7.97 billion, a price-to-earnings ratio of -278.33, a PEG ratio of 4.54 and a beta of 0.95. The company’s 50 day simple moving average is $155.62 and its 200 day simple moving average is $148.36. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. Repligen Co. has a fifty-two week low of $113.50 and a fifty-two week high of $187.25.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03. The company had revenue of $167.55 million for the quarter, compared to analysts’ expectations of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. As a group, sell-side analysts anticipate that Repligen Co. will post 1.72 EPS for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.